Intuitive Surgical upgraded by Morgan Stanley with a new price target
$ISRG
Industrial Specialties
Health Care
Morgan Stanley upgraded Intuitive Surgical from Equal-Weight to Overweight and set a new price target of $650.00 from $522.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $522.00 → $650.00 | Equal-Weight → Overweight | Morgan Stanley |
| 8/2/2024 | $380.00 → $510.00 | Neutral → Buy | Redburn Atlantic |
| 7/10/2024 | $462.00 → $512.00 | Buy | Citigroup |
| 5/30/2024 | $500.00 | Buy | Goldman |
| 11/17/2023 | $318.00 | Buy | HSBC Securities |
| 7/19/2023 | $377.00 | Outperform | Robert W. Baird |
| 4/19/2023 | $240.00 → $270.00 | In-line | Evercore ISI |
| 4/19/2023 | $305.00 → $317.00 | Buy | Citigroup |
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)
SUNNYVALE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2024 financial results ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Financial and Operational Highlights Fourth quarter 2024 worldwide da Vinci procedures grew approximately 18% compared with the fourth quarter of 2023.Full year 2024 worldwide da Vinci procedures grew approximately 17% compared with 2023. The Company expects worldwide da Vinci procedures to i
SUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2024. Q3 Highlights Worldwide da Vinci procedures grew approximately 18% compared with the third quarter of 2023.The Company placed 379 da Vinci surgical systems, compared with 312 in the third quarter of 2023. The third quarter 2024 da Vinci surgical system placements included 110 da Vinci 5 systems.The Company grew its da Vinci surgical system installed base to 9,539 systems as of Septemb
SUNNYVALE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2024. Q2 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the second quarter of 2023.The Company placed 341 da Vinci surgical systems, compared with 331 in the second quarter of 2023. The second quarter 2024 da Vinci surgical system placements included 70 da Vinci 5 systems.The Company grew its da Vinci surgical system installed base to 9,203 systems as of June 30, 2024, an increase of 14%
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the
Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit
SUNNYVALE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2024 financial results ahead of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Financial and Operational Highlights Fourth quarter 2024 worldwide da Vinci procedures grew approximately 18% compared with the fourth quarter of 2023.Full year 2024 worldwide da Vinci procedures grew approximately 17% compared with 2023. The Company expects worldwide da Vinci procedures to i
SUNNYVALE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced executive leadership promotions in support of the company's continued global growth in pursuit of its mission to advance minimally invasive care. Henry Charlton has been promoted to the role of executive vice president and chief commercial and marketing officer. A 21-year Intuitive veteran, Charlton has served in key leadership roles across the business, including the U.S., European, APAC, and global distribution and commercial organizations, regional marketing, global customer services and comm
Analysis included 230 studies—a mix of randomized, prospective, and database research SUNNYVALE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:ISRG) The peer-reviewed Annals of Surgery published a meta-analysis of 30-day surgical outcomes across seven oncological surgical procedures, comparing robotic, laparoscopic, and open surgical approaches. The study covered a 12-year timeframe and analyzed 230 studies from 22 countries: 34 randomized controlled trials, 74 prospective studies, and 122 database reviews. Each surgical approach represented more than a million procedures. The meta-analysis, conducted by scientists from Intuitive and Massachusetts General Hospital, demonstrated mult
Morgan Stanley upgraded Intuitive Surgical from Equal-Weight to Overweight and set a new price target of $650.00 from $522.00 previously
Redburn Atlantic upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $510.00 from $380.00 previously
Citigroup reiterated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $512.00 from $462.00 previously
8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)
8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)
144 - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)
SC 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)